The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. [electronic resource]
Producer: 20120325Description: 463-74 p. digitalISSN:- 1791-7530
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Cycle Checkpoints -- drug effects
- Cell Growth Processes -- drug effects
- Cell Line, Tumor
- Cytarabine -- administration & dosage
- Dexamethasone -- administration & dosage
- Doxorubicin -- administration & dosage
- Drug Resistance, Neoplasm
- Drug Synergism
- Humans
- Imidazoles -- administration & dosage
- Jurkat Cells
- Leukemia, B-Cell -- drug therapy
- Oncogene Protein v-akt -- antagonists & inhibitors
- Phosphatidylinositol 3-Kinase -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Quinolines -- administration & dosage
- Signal Transduction
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.